tbuckley/cabot-search huggingface dataset:
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios at the time of chemoradiation to predict survival in resected pancreatic cancer patients.
Authors: Vanessa Xu, Enid Choi, Alexandra Hanlon, William Regine, Michael David Chuong
Journal: Journal of Clinical Oncology (2015)

452 Background: Higher pre-treatment neutrophil-to-lymphocyte ratio (NLR) and lower platelet-to-lymphocyte ratio (PLR) are independent predictors for worse survival in cancer patients. The effect of chemoradiation (CRT) on NLR and PLR in pancreatic cancer patients who also undergo surgical resection has not been reported. Methods: A retrospective review was performed of pancreatic cancer patients treated at our institution with CRT either prior to or after surgery with curative intent. Overall survival was evaluated using Kaplan-Meier method. Univariate and multivariate Cox regression models were applied to evaluate the independent prognostic significance of NLR and PLR. Results: After excluding patients who did not have surgery, who received palliative radiation doses, or who had incomplete medical records, 81 out of 282 patients remained with median age 62 years (35-86). Of these, 24 (29.6%) were borderline resectable (BR) and received preoperative CRT while 57 (70.4%) received adjuvant CRT. Median total dose and number of fractions were 50.4 Gy (30-59.4) and 28 (5-33), respectively. Median pre-CRT and post-CRT NLR were 2.9 and 7.8, respectively. Median pre-CRT and post-CRT PLR were 211.3 and 457.5, respectively. Most patients had a decrease in NLR (85.2%) and PLR (72.8%) after CRT, with median changes of -4.95 for NLR and -178.33 for PLR. Cox proportional hazards analysis showed a trend towards significance for pre-CRT NLR (p=.08) regarding OS. A significant relationship was found between relapse free survival and both pre-CRT NLR (p=0.02) and PLR (p=0.01). The difference or percent change of neither NLR nor PLR was found to correlate with clinical outcomes. Conclusions: This is the first study to evaluate the effect of CRT on NLR and PLR in resected pancreas cancer patients. Similar to other reports, our data indicate that a significant relationship exists between NLR, PLR, and clinical outcomes. Identification of clinically meaningful NLR and PLR cut-off points for resected pancreatic cancer patients who also receive CRT is needed.
Seven day services will need 4000 extra doctors, says leaked report
Authors: Ingrid Torjesen
Journal: BMJ (2016)

Up to 4000 more doctors will be needed to staff seven day services in the NHS in England, a leaked report has said.

The internal Department of Health report, leaked to the Guardian , said that 11 000 more staff would be needed, including 4000 more doctors (1600 consultants, 1500 registrars, and 900 junior doctors).1 These numbers were “calculated by increasing the number of staff at the weekend . . . in order to match weekdays.”

A seven day service would cost an additional £900m (€1.2m; $1.3m) a year after “benefits such as reduced length of stay and reduced admissions” were taken into account, said the report, quoting figures from another unpublished report, commissioned from the consultancy group Deloitte …
Neurological sequelae of healthcare-associated sepsis in very-low-birthweight infants: Umbrella review and evidence-based outcome tree
Authors: Sebastian Haller, Philipp Deindl, Alessandro Cassini, Carl Suetens, Walter Zingg, Muna Abu Sin, Edward Velasco, Bettina Weiss, Tanja Ducomble, Madlen Sixtensson, Tim Eckmanns, Thomas Harder
Journal: Eurosurveillance (2016)

Sepsis is a frequent cause of death in very-low-birthweight infants and often results in neurological impairment. Its attributable risk of sequelae has not been systematically assessed. To establish an outcome tree for mapping the burden of neonatal sepsis, we performed systematic literature searches to identify systematic reviews addressing sequelae of neonatal sepsis. We included cohort studies and performed meta-analyses of attributable risks. Evidence quality was assessed using GRADE. Two systematic reviews met inclusion criteria. The first included nine cohort studies with 5,620 participants and five outcomes (neurodevelopmental impairment, cerebral palsy, vision impairment, hearing impairment, death). Pooled risk differences varied between 4% (95% confidence interval (CI):2-10) and 13% (95% CI:5-20). From the second review we analysed four studies with 472 infants. Positive predictive value of neurodevelopmental impairment for later cognitive impairment ranged between 67% (95% CI:22-96) and 83% (95% CI:36-100). Neonatal sepsis increases risk of permanent neurological impairment. Effect size varies by outcome, with evidence quality being low to very low. Data were used to construct an outcome tree for neonatal sepsis. Attributable risk estimates for sequelae following neonatal sepsis are suitable for burden estimation and may serve as outcome parameters in interventional studies.
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma
Authors: Harvey I. Pass, Chandra Goparaju, Osvaldo Espin-Garcia, Jessica Donington, Michele Carbone, Devalben Patel, Zhuo Chen, Ronald Feld, John Cho, Shirish Gadgeel, Antoinette Wozniak, Abraham Chachoua, Natasha Leighl, Ming-Sound Tsao, Marc de Perrot, Wei Xu, Geoffrey Liu
Journal: Journal of Thoracic Oncology (2016)
UK’s health and social care spending plans: more of the same?
Authors: John Appleby
Journal: BMJ (2015)

Nearly half of next year’s NHS funding boost will come from cuts to other health services, finds John Appleby 

Five years ago the new coalition government set itself the task of repairing the United Kingdom’s finances. Through a combination of public spending cuts and tax rises, the government’s central macroeconomic plans in 2010 were to cut day to day borrowing and reduce the nation’s overall debt. By this year the fiscal repair job was meant to be complete.

Unfortunately, none of the government’s macroeconomic targets has been met. Borrowing is 3.9% of gross domestic product (GDP), not 1.1% as planned; the structural current deficit is 3.4% (£640.7bn (€920bn; $970bn), not zero); and, at over 83% of GDP, the national debt is 16 percentage points higher than planned.1 2

Instead of the sunny uplands of a booming economy and nearer to normal long run levels of deficit and debt, the government—intent on sticking to its debt and deficit reduction policies—is embarking on another round of spending cuts.

This week’s spending review has now set …
Thrombopoietin receptor is required for the oncogenic function of CALR mutants
Authors: H Nivarthi, D Chen, C Cleary, B Kubesova, R Jäger, E Bogner, C Marty, C Pecquet, W Vainchenker, S N Constantinescu, R Kralovics
Journal: Leukemia (2016)

PH performed the cell culture, genotyping and next-generation sequencing (NGS) experiments, interpreted the results and wrote the manuscript.ACM and SL collected clinical data and contributed in follow-up of the patient.RB coordinated HSC transplantation and contributed in the material collection.RT designed NGS assays.LS performed cytological and flow cytometry analysis of patient samples.DB and CM performed the standard molecular and chimerism analysis.
Vitamin A and Childhood Mortality
Journal: New England Journal of Medicine (1991)

﻿Laxmi Rahmathulla THE article on 'Vitamin A and Child Mortality' (EPW) appears to be based mainly on the New England Journal of Medicine (NEJM) report and partial information gathered at a workshop. The goal of the workshop was to promote dietary consumption of vitamin A and not a discus- sion on methodologies. However, some points raised are valid and we will attempt to answer them. Most of the other points raised have easy answers and question need not have been raised if a personal detailed discussion with the author was attempted. Attempts have been made to invalidate the study without looking at all the data available, The focus on the Madurai study appears to be in retaliation to the fact that the study received favourable editorials in the NEJM and The Lancet and some sort of polarisation between the west and the developing countries is attempted which should not be the view of any scientist. It will be a pity if scientific research becomes a victim of politics.
A phase II study of gemcitabine and liposomal doxorubicin (Lipo-Dox) as first line chemotherapy in the treatment of metastatic breast cancer
Authors: N. Yao, W. Kao, T. Chao, R. Hsieh, J. Lin, C. Su, S. Lo
Journal: Journal of Clinical Oncology (2006)

10688 Background: To determine the overall objective response rate (ORR) of Lipo-Dox plus Gemcitabine in patients with metastatic breast cancer. Patients and Methods: We are conducting an open-label, non-comparative phase II clinical trial in Simon’s 2-stage optimal design to assess the efficacy and the safety of the treatment with Gemcitabine (Gems) plus Liposomal Doxorubicin (Lipo-Dox) in patients with metastatic breast cancer. All eligible subjects received Lipo-Dox 25 mg/m 2 intravenous infusion over 1 hr and follow by gemcitabine 800 mg/m 2 intravenously (iv) over 30 minutes on day 1, and receive gemcitabine 800 mg/m 2 intravenously (iv) over 30 minutes only on day 8 in a 21-day cycle. Results: Between July 2004 and December 2005, a total of 21 patients were enrolled in the study and total of 136 cycles of chemotherapy were delivered with a median of six per patients (range 1–16). 17 patients (80.8%) who had at least one post-treatment evaluation and exposed to at least two cycles of treatment were included in this report. Characteristics of the 17 patients: All females; median age 52 years (range 36 - 68); 16 pts had a performance status (PS) of 0 or 1 and 1 had a PS of 2 (ECOG scale); Histology: All metastatic breast cancer. The response assessment of the 17 patients: Complete response was observed in 2, partial response in 5, stable disease in 8, and progressive disease in 2 patients. Overall response rate was 41.17%. Major grade 3/4 hematological toxicities were neutropenia in 9 pts, thrombocytopenia in 2 pt and leukopenia in 5 pts. Peripheral neuropathy was noted in 1 patient (grade 2). Other toxicities occurred during the treatment cycles were all manageable or tolerable. Patient recruitment, treatment and follow-up are still ongoing. Conclusion: Liposomal Doxorubicin used in the regimen reduces the incidence of alopecia (hair loss) to grade 1 compare to the conventional doxorubicin. This study, with an overall response rate of 41.1% (CR+PR) and a rate of stable disease of 47.05%, has shown a good activity with mild and acceptable toxicities of Gemcitabine (Gems) plus Liposomal Doxorubicin (Lipo-Dox) regimen in patients with metastatic breast cancer. No significant financial relationships to disclose.
An Established Cultured Cell Line (HBT-39) From Human Breast Carcinoma
Authors: Ernest J. Plata, Tadao Aoki, Diane D. Robertson, Elizabeth W. Chu, Brenda I. Gerwin
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article An Established Cultured Cell Line (HBT-39) From Human Breast Carcinoma Get access Ernest J. Plata, Ernest J. Plata Immunology Section, Viral Leukemia and Lymphoma Branch, National Cancer Institute,4Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Tadao Aoki, Tadao Aoki Immunology Section, Viral Leukemia and Lymphoma Branch, National Cancer Institute,4Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Diane D. Robertson, Diane D. Robertson Immunology Section, Viral Leukemia and Lymphoma Branch, National Cancer Institute,4Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Elizabeth W. Chu, Elizabeth W. Chu Immunology Section, Viral Leukemia and Lymphoma Branch, National Cancer Institute,4Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Brenda I. Gerwin Brenda I. Gerwin Immunology Section, Viral Leukemia and Lymphoma Branch, National Cancer Institute,4Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 50, Issue 4, April 1973, Pages 849–862, https://doi.org/10.1093/jnci/50.4.849 Published: 01 April 1973 Article history Received: 23 August 1972 Accepted: 20 November 1972 Published: 01 April 1973
Vasectomy and increased risk of prostate cancer [letter]
Authors: Sidney S, Quesenberry Cp, Sadler Mc, Cattolica Ev
Journal: JAMA (1993)

The study of Giovannucci on the relationship of vasectomy to prostate cancer relied on self-report by cohort members to identify incident prostate cancers and confirmed these cases by review of medical records. Self-report of prostate cancer may potentially result in significant underascertainment.  In the Kaiser Permanente Study of vasectomy and prostate cancer incident prostate cases were identified in a cohort of multiphasic health checkup (MHC) examinees by linking the medical record number of the MHC examinee to computerized tumor registry and hospitalization records.  Of the 38 MHC cohort members who had a second MHC cancer at that second MHC on a self-administered questionnaire.  The denial of the cancer may contribute to such a high rate of underreporting of prostate cancer.  Also small prostate cancers incidentally discovered by prostatectomies performed for benign prostatic hypertrophy (stage ]A1) possibly are downplayed by the urologist because standard practice has been not to treat such cancers. Results from cohort studies that rely on self-report of prostate cancer could be strengthened by comparison of incidence rates with data from Surveillance Epidemiology and End Results Program (SEER) cancer incidence rates.  Age-specific prostate cancer incidence rates in White men in the Kaiser Permanente Study cohort were compared with follow-up through 1990 with SEER rates between 1985 and 1989 in age groups with 10 or more incident cancers.  The average of the age-specific ratios of Kaiser Permanent/SEER rates was 0.99 as would be expected as registry data were used to identify prostate cancers in this cohort.  Since underascertainment is a potential source of bias cohort studies relying on self-report should provide comparisons to standard incidence rates.
Chemo-selection of patients (pts) for organ preservation in advanced laryngeal cancer: Failure of chemotherapy (CT) as the sole treatment for complete histologic responders (CHR) to neoadjuvant chemotherapy
Authors: F. P. Worden, G. Wolf, A. Eisbruch, J. Lee, C. Bradford, D. Chepeha, T. Teknos, M. Prince, N. Hogikyan, C. Tsien, S. Urba
Journal: Journal of Clinical Oncology (2006)

5560 Background: We conducted a phase II organ preservation trial for stage III/IV laryngeal cancer pts in an attempt to identify pts, who were CHR after 1 cycle of induction CT, who might be curable with CT alone. Methods: Pts received 1 cycle of cisplatin 100 mg/m 2 &amp; 5-FU 1000 mg/m 2 /day x 5 days (P+5FU). CHR received 1 cycle of P+5FU, followed by weekly docetaxel (D) 35 mg/m 2 x 3 wks, followed by 1 cycle of P+5FU, &amp; no radiotherapy (RT). Pts with &gt;50% (but &lt; 100%) response (PR) received chemoradiation (CRT) with 70 Gy &amp; P 100 mg/m 2 days 1, 22, &amp; 43. Pts with &lt; 50% response underwent laryngectomy. Final planned tumor assessment with direct laryngoscopy with biopsy was done 8 wks after CRT or 3 wks after the last cycle of P+5FU (CT alone arm). CHR after CT alone received 2 cycles of P+5FU alternating with 2 cycles of D. CHR after CRT received 2 cycles of P+5FU, &amp; pts with residual disease had planned salvage surgery. Results: 32 eligible pts were enrolled, 24 M; 8 F; median age 56, stage III/IV- 7/25. After 1 cycle CT, 4 pts (13%) had CHR &amp; received CT alone; 24 (75%) had PR &amp; received CRT; 3 had surgery; &amp; 1 refused surgery. Of pts who had CT alone, 4/4 had regional failures; 3/4 underwent neck dissection &amp; 1/4 had laryngectomy &amp; neck dissection; all had adjuvant RT because of multiple nodes or extracapsular spread; 3/4 are alive without disease &amp; 1/4 is dead of complications. 5/24 who received CRT failed; 2/24 had surgery &amp; 3/24 were unresectable. Toxicity: Gr 3/4 granulocytopenia 19%, Gr 3/4 mucositis with CT alone 12.5%. Median follow-up is 16.5 months. 2 yr overall survival is 88.2% (95% CI = 75.3%, 100%). 1 yr disease-free survival (DFS) is 81.8% (CI=67.2%, 96.5%). 2 yr DFS is 76% (CI=58.4%, 93.5%). The proportion of pts alive &amp; free of cancer with intact larynx at 1 yr is 69.1% (CI = 51.9%, 86.3%) &amp; at 2 yrs is 63.8% (CI=45%, 82.5%). 1 pt developed distant metastases. Larynx preservation was achieved in 24 pts (75%). Conclusions: CT alone is not an effective strategy for advanced laryngeal cancer pts, even in CHR after 1 cycle of induction CT, due to high nodal failure rate. Planned integration of early regional control by surgery or lower-dose RT may be necessary to allow treatment approaches that spare selected pts high-dose RT. No significant financial relationships to disclose.
Abstract 16258: Anxiety, Depression and Age: Implications for Women With Heart Failure
Authors: Jo-Ann Eastwood, Lynn V Doering, Terry A Lennie, Gia Mudd-Martin, Martha J Biddle, Debra K Moser
Journal: Circulation (2013)

Anxiety and depression are common in patients with HF. Both are associated with poor outcomes in HF, including high morbidity and healthcare resource use. In women with HF, the relationship of anxi...
Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients
Authors: Alberto Rocci, Manuela Gambella, Paola Omedè, Daniela Drandi, Francesca Gay, Francesca Patriarca, Federica Cavallo, Maria Teresa Petrucci, Caravita Tommaso, Giulia Benevolo, Norbert Pescosta, Stefania Oliva, Massimo Offidani, Vittorio Montefusco, Anna Marina Liberati, Antonietta Pia Falcone, Stelvio Ballanti, Tonino Spadano, Tommasina Guglielmelli, Pellegrino Musto, Renato Zambello, Francesco Di Raimondo, Marco Ladetto, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2013)
Phase I dose escalation study of E7080, a novel anti-angiogenic multikinase inhibitor, in Japanese patients with advanced solid tumors
Authors: K. Yamada, Y. Fujiwara, N. Yamamoto, Y. Yamada, S. Suzuki, N. Kobayashi, F. Koizumi, K. Nishio, T. Tamura
Journal: Journal of Clinical Oncology (2007)

14099 Background: E7080 selectively inhibits receptor phosphorylation of vascular endothelial growth factor (VEGF), platelet- derived growth factor (PDGF), fibroblast growth factor (FGF) and suppresses tumor angiogenesis and growth in preclinical studies. Methods: E7080 was orally administered to Japanese patients with advanced solid tumors twice daily by a 2 week-on 1 week-off schedule. The primary objectives were to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and the recommended dose for further study. The secondary objectives were to evaluate pharmacokinetics (PK), pharmacogenomics, and efficacy. Results: Twelve patients have been enrolled into cohorts of 1, 2, 4 or 8 mg/day. Major toxicities were hypertension and hyperlipidemia. Thus far, no DLTs or severe toxicities were reported. PK analysis in cohorts of 1, 2 and 4 mg/day showed the dose-proportional increase of Cmax and AUC. Three patients in cohorts of 1 and 2 mg/day experienced long stable disease (SD) for 18 weeks or longer. One patient with colorectal cancer in 4 mg/day cohort showed significant tumor shrinkage of multiple pulmonary metastasis. Biomarkers such as plasma angiogenic proteins and cytokines, circulating endothelial cells and circulating endothelial progenitor cells are exploratively evaluated. Conclusions: E7080 is well tolerated at doses up to 8 mg/day by a 2 week-on 1 week-off schedule. Some patients experienced clinical benefit without severe toxicity. MTD has not been reached and enrollment is ongoing. No significant financial relationships to disclose.
Abstract 14817: Iron Restricted Pair Feeding Attenuates Hypertension and Renal Damage in a Rat Model of Chronic Kidney Disease
Authors: Yoshiro Naito, Hisashi Sawada, Makiko Oboshi, Aya Fujii, Manami Hosokawa, Toshihiro Iwasaku, Yoshitaka Okuhara, Daisuke Morisawa, Akiyo Eguchi, Shinichi Hirotani, Toshiaki Mano, Takeshi Tsujino, Tohru Masuyama
Journal: Circulation (2014)

Introduction: Iron is associated with the pathogenesis of chronic kidney disease (CKD). We have previously shown that dietary iron restriction prevented the development of renal damage in a rat model of CKD. Meanwhile, iron deficiency is associated with appetite loss. In addition, it is reported that calorie restriction prevented the development of end-stage renal pathology in a rat model of CKD. Thus, it is concerned that beneficial effects of iron restriction on renal damage may depend on calorie restriction. Here, we investigate the effects of pair-feeding iron restriction on renal damage in a rat model of CKD. Methods: First, to determine the food intake, Sprague-Dawley (SD) rats were randomly given an ad libitum normal diet or an iron-restricted diet for 16 weeks, and the food intake were measured every 1 week. Second, CKD was induced by 5/6 nephrectomy in SD rats, and CKD rats were given either pair-feeding normal or iron-restricted diet for 16 weeks. Results: The food intake was fewer in the iron-r...
CTC toxicity grades over-estimate the distress caused by chemotherapy side effects in women treated for metastatic breast cancer
Authors: L. K. Dawson, M. T. Fallon, D. A. Cameron
Journal: Journal of Clinical Oncology (2004)

8085 Background: Chemotherapy toxicity criteria (CTC) routinely collected by health professionals to record the severity of chemotherapy side effects may neither reflect the associated distress and quality of life impact nor represent patients' viewpoints. Methods: Staff and patients recorded CTC data on standard departmental charts and scored the associated distress and impact on quality of life on Likert scales for anthracycline or taxane-based chemotherapy regimens for advanced breast cancer. The worthwhileness of treatment was also recorded at the end of chemotherapy. Results: 45 patients and the staff treating them completed records for at least 1 cycle of treatment. One third of patients experienced grade ≥2 toxicities. The distress and impact on quality of life patients associate with toxicities is less than toxicity grade except for vomiting and diarrhoea. Staff impressions of patients' views of side effects on seem to be influenced by toxicity grade. Patients and staff differ in their rating of distress except for vomiting and diarrhoea and of the quality of life impact except for vomiting. Ratings of the worthwhileness of treatment were available from doctors and nurses for 30 patients. Patients (χ2 trend= 0.20 (p=NS)) and doctors (χ2 trend= 3.47 (p<0.1) were not influenced by the response to treatment but nurses were (χ2 trend= 4.72 (p<0.05)). There was little agreement between groups as to the worthwhileness of treatment (Kappa scores: patients and nurses =0.38, patients and doctors = −0.09, nurses and doctors=0.07). Conclusions: CTC grades do not accurately reflect the distress and quality of life impact of chemotherapy side effects. With the exception of vomiting, the distress and quality of life impact of chemotherapy toxicity is less than the CTC grading. This has implications for choosing regimens based on staff -reported CTC gradings. No significant financial relationships to disclose.